Hikma Launches First Once-Daily Generic Victoza In The US

As The Firm Celebrated Several Other Generic Drug Launches In The American Market

The FDA delivered its “Christmas gift” of approving Hikma’s generic Victoza, the first once-daily liraglutide injectable on the US market.

Hands in medical gloves holding a Christmas gift
(Shutterstock)

Hikma’s CEO Riad Mishlawi must have been on a good list as his wish to get US approval for the firm’s generic liraglutide around Christmas came true.

The US Food and Drug Administration approved the generic rival to Novo Nordisk’s Victoza as the first once-daily liraglutide injectable.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

US Supreme Court Requests Solicitor General Input On Hikma Skinny Label Case

 
• By 

The US Supreme Court is seeking a brief “expressing the views of the United States,” following the US Federal Circuit’s decision to reopen Amarin’s claim of induced infringement against Hikma relating to its ‘skinny-label’ generic Vascepa (icosapent ethyl) product.

Viatris Targets Gilead’s Odefsey HIV Blockbuster In Europe With CHMP Recommendation

 
• By 

Viatris has secured two positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use for generics to two blockbusters: Gilead’s HIV drug Odefsey and Boehringer’s IPF treatment Ofev, with a path to approvals possible in 67 days.

AAM Celebrates Court Backing Over Minnesota Pricing Law

 
• By 

The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.

Accord And Sandoz Remain Frustrated As Dutch Xtandi Patent Is Latest To Hold Firm

 
• By 

In a further setback for generics manufacturers, the District Court of The Hague has upheld the validity of a key Xtandi (enzalutamide) patent and its Dutch supplementary protection certificate, rejecting Sandoz and Accord’s challenge based on lack of inventive step.

More from Generics Bulletin

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By 

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.

Accord And Sandoz Remain Frustrated As Dutch Xtandi Patent Is Latest To Hold Firm

 
• By 

In a further setback for generics manufacturers, the District Court of The Hague has upheld the validity of a key Xtandi (enzalutamide) patent and its Dutch supplementary protection certificate, rejecting Sandoz and Accord’s challenge based on lack of inventive step.

Medicines For Europe Sets Out Trade Priorities

 
• By 

As Medicines for Europe gears up for a pair of conferences in Brussels next week, the organization has set out trade policy recommendations to strengthen access to medicines and the competitiveness of EU manufacturing, in a seminar with representatives from the European Commission and member states.